Résumé
Context: hormone therapy used in the treatment of breast cancer, could be responsible for pelvic floor disorders, by its anti-estrogenic action. Objective: the main objective of this study was to assess the prevalence of pelvic floor disorders in women treated with hormone therapy for localized breast cancer. Methods: a comparative prospective study was conducted at the Montpellier Cancer Institute and the University Hospital of Montpellier. Women over 50 years of age, menopausal, not metastatic, who underwent surgery after June 2015 with hormone-sensitive or non-sensitive breast cancer could be included in 2 distinct groups: Hormone Therapy Group (HT+) or without Hormone Therapy Group (HT-). Patients answered two validated questionnaires: PFDI 20 and PFIQ7. The primary outcome was the presence of urinary incontinence (UI). Results: 246 patients were included from June 2020 to June 2021. The prevalence of UI was higher in the HT+ group (57.93% vs 36.59%, OR 2.39 [95% CI: 1.38-4.12], p = 0.002). The PFDI-20 score was higher in HT+ patients (28.13 vs 14.58, p< 0.001). The UI risk factors found in multivariate analysis were number of vaginal deliveries ≥ 2 (OR 2.16 [95% CI 1.22-3.80], p=0.007) and hormone therapy intake (OR 2.37 [95% CI 1.33-4.22], p=0.003). The impact on quality of life (PFIQ7 score) was greater in the HT+ group (cIRR 1.86; [95% CI: 1.21-2.85]; p= 0.004). Conclusion: this study found out an increase in urinary incontinence in patients followed for breast cancer and treated with hormone therapy which should lead to a specific treatment of these patients.